FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2286960892> ?p ?o ?g. }

• W2286960892 endingPage "3570" @default.
• W2286960892 startingPage "3560" @default.
• W2286960892 abstract "Abstract Purpose: Malignant rhabdoid tumor (MRT) and atypical teratoid rhabdoid tumors (ATRT) are rare aggressive undifferentiated tumors primarily affecting the kidney and CNS of infants and young children. MRT are almost exclusively characterized by homozygous deletion or inactivation of the chromatin remodeling gene SMARCB1. SMARCB1 protein loss leads to direct impairment of chromatin remodeling and we have previously reported a role for this protein in histone acetylation. This provided the rationale for investigating the therapeutic potential of histone deactylase inhibitors (HDACi) in MRT. Experimental Design: Whereas previously HDACis have been used at doses and schedules that induce cytotoxicity, in the current studies we have tested the hypothesis, both in vitro and in vivo, that sustained treatment of human MRT with low-dose HDACi can lead to sustained cell growth arrest and differentiation. Results: Sustained low-dose panobinostat (LBH589) treatment led to changes in cellular morphology associated with a marked increase in the induction of neural, renal, and osteoblast differentiation pathways. Genome-wide transcriptional profiling highlighted differential gene expression supporting multilineage differentiation. Using mouse xenograft models, sustained low-dose LBH589 treatment caused tumor growth arrest associated with tumor calcification detectable by X-ray imaging. Histological analysis of LBH589-treated tumors revealed significant regions of ossification, confirmed by Alizarin Red staining. Immunohistochemical analysis showed increased TUJ1 and PAX2 staining suggestive of neuronal and renal differentiation, respectively. Conclusions: Low-dose HDACi treatment can terminally differentiate MRT tumor cells and reduce their ability to self-renew. The use of low-dose HDACi as a novel therapeutic approach warrants further investigation. Clin Cancer Res; 22(14); 3560–70. ©2016 AACR." @default.
• W2286960892 created "2016-06-24" @default.
• W2286960892 creator A5006127122 @default.
• W2286960892 creator A5030613782 @default.
• W2286960892 creator A5042123660 @default.
• W2286960892 creator A5046492376 @default.
• W2286960892 creator A5052652340 @default.
• W2286960892 creator A5055468599 @default.
• W2286960892 creator A5060696449 @default.
• W2286960892 creator A5066009774 @default.
• W2286960892 creator A5074906910 @default.
• W2286960892 creator A5079225408 @default.
• W2286960892 creator A5081126037 @default.
• W2286960892 creator A5086284080 @default.
• W2286960892 date "2016-07-14" @default.
• W2286960892 modified "2023-09-27" @default.
• W2286960892 title "Low-Dose Histone Deacetylase Inhibitor Treatment Leads to Tumor Growth Arrest and Multi-Lineage Differentiation of Malignant Rhabdoid Tumors" @default.
• W2286960892 cites W1820439053 @default.
• W2286960892 cites W1965029808 @default.
• W2286960892 cites W1977155786 @default.
• W2286960892 cites W1979832500 @default.
• W2286960892 cites W1986235688 @default.
• W2286960892 cites W1995359023 @default.
• W2286960892 cites W199598393 @default.
• W2286960892 cites W2000156285 @default.
• W2286960892 cites W2008105436 @default.
• W2286960892 cites W2008638145 @default.
• W2286960892 cites W2011445314 @default.
• W2286960892 cites W2012068657 @default.
• W2286960892 cites W2015053302 @default.
• W2286960892 cites W2032718598 @default.
• W2286960892 cites W2035706478 @default.
• W2286960892 cites W2042962536 @default.
• W2286960892 cites W2049002013 @default.
• W2286960892 cites W2050403417 @default.
• W2286960892 cites W2055279984 @default.
• W2286960892 cites W2071710018 @default.
• W2286960892 cites W2077264797 @default.
• W2286960892 cites W2087726661 @default.
• W2286960892 cites W2100805638 @default.
• W2286960892 cites W2100874086 @default.
• W2286960892 cites W2109113060 @default.
• W2286960892 cites W2111907637 @default.
• W2286960892 cites W2115593774 @default.
• W2286960892 cites W2117180730 @default.
• W2286960892 cites W2122914905 @default.
• W2286960892 cites W2132821142 @default.
• W2286960892 cites W2140409715 @default.
• W2286960892 cites W2144793849 @default.
• W2286960892 cites W2169589032 @default.
• W2286960892 doi "https://doi.org/10.1158/1078-0432.ccr-15-2260" @default.
• W2286960892 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26920892" @default.
• W2286960892 hasPublicationYear "2016" @default.
• W2286960892 type Work @default.
• W2286960892 sameAs 2286960892 @default.
• W2286960892 citedByCount "38" @default.
• W2286960892 countsByYear W22869608922016 @default.
• W2286960892 countsByYear W22869608922017 @default.
• W2286960892 countsByYear W22869608922018 @default.
• W2286960892 countsByYear W22869608922019 @default.
• W2286960892 countsByYear W22869608922020 @default.
• W2286960892 countsByYear W22869608922021 @default.
• W2286960892 countsByYear W22869608922022 @default.
• W2286960892 countsByYear W22869608922023 @default.
• W2286960892 crossrefType "journal-article" @default.
• W2286960892 hasAuthorship W2286960892A5006127122 @default.
• W2286960892 hasAuthorship W2286960892A5030613782 @default.
• W2286960892 hasAuthorship W2286960892A5042123660 @default.
• W2286960892 hasAuthorship W2286960892A5046492376 @default.
• W2286960892 hasAuthorship W2286960892A5052652340 @default.
• W2286960892 hasAuthorship W2286960892A5055468599 @default.
• W2286960892 hasAuthorship W2286960892A5060696449 @default.
• W2286960892 hasAuthorship W2286960892A5066009774 @default.
• W2286960892 hasAuthorship W2286960892A5074906910 @default.
• W2286960892 hasAuthorship W2286960892A5079225408 @default.
• W2286960892 hasAuthorship W2286960892A5081126037 @default.
• W2286960892 hasAuthorship W2286960892A5086284080 @default.
• W2286960892 hasBestOaLocation W22869608921 @default.
• W2286960892 hasConcept C104317684 @default.
• W2286960892 hasConcept C142724271 @default.
• W2286960892 hasConcept C167227067 @default.
• W2286960892 hasConcept C177450382 @default.
• W2286960892 hasConcept C2777865847 @default.
• W2286960892 hasConcept C2778305200 @default.
• W2286960892 hasConcept C2778467961 @default.
• W2286960892 hasConcept C2780225316 @default.
• W2286960892 hasConcept C2780789225 @default.
• W2286960892 hasConcept C502942594 @default.
• W2286960892 hasConcept C54355233 @default.
• W2286960892 hasConcept C64927066 @default.
• W2286960892 hasConcept C71723506 @default.
• W2286960892 hasConcept C71924100 @default.
• W2286960892 hasConcept C86803240 @default.
• W2286960892 hasConceptScore W2286960892C104317684 @default.
• W2286960892 hasConceptScore W2286960892C142724271 @default.
• W2286960892 hasConceptScore W2286960892C167227067 @default.
• W2286960892 hasConceptScore W2286960892C177450382 @default.
• W2286960892 hasConceptScore W2286960892C2777865847 @default.

• next